Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

InMed Pharmaceuticals Inc. (INM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.73-0.22 (-2.77%)
At close: 04:00PM EDT
7.43 -0.30 (-3.88%)
After hours: 07:05PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close7.95
Open7.90
Bid7.42 x 1000
Ask8.17 x 1100
Day's Range7.12 - 8.23
52 Week Range4.95 - 59.25
Volume96,706
Avg. Volume921,359
Market Cap7.025M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-1.16
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • InMed Pharmaceuticals Inc.
    Daily – Vickers Top Insider Picks for 10/06/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update

    VANCOUVER, British Columbia, Sept. 23, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3ca

  • GlobeNewswire

    InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022

    VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a

  • GlobeNewswire

    InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

    VANCOUVER, British Columbia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, today announced the closing of its previously announced private placement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share (or pre-funded warrant in lieu thereof) priced at-the-market under

Advertisement
Advertisement